Akash Nahar

Statistics

Publications

Citations

741

H-Index

Active since

2018

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Bologna

Princess Margaret Cancer Centre

Jewish General Hospital

The University of Texas MD Anderson Cancer Center

Akash Nahar is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, immunotherapy, and hodgkin lymphoma treatment.

Publications per year

2018–2024

Publications

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee et al. · Blood · 2019 · 329 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

Medicine, Oncology, Pharmacology +15

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

Philippe Armand, John Kuruvilla, Jean‐Marie Michot et al. · Blood Advances · 2020 · 54 citations · Full text

Medicine, Hematology, Oncology +17

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · Journal of Clinical Oncology · 2020 · 34 citations

Medicine, Oncology, Pharmacotherapy +17

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro et al. · Blood Advances · 2021 · 20 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

1–5 of 8